Lexicon Pharmaceuticals (LXRX) Competitors $0.80 0.00 (-0.38%) (As of 02:08 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LXRX vs. AVEO, IRWD, EBS, RIGL, SGMO, CDXS, XOMA, VNDA, VSTM, and ACHVShould you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include AVEO Pharmaceuticals (AVEO), Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Sangamo Therapeutics (SGMO), Codexis (CDXS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), and Achieve Life Sciences (ACHV). These companies are all part of the "biotechnology" industry. Lexicon Pharmaceuticals vs. AVEO Pharmaceuticals Ironwood Pharmaceuticals Emergent BioSolutions Rigel Pharmaceuticals Sangamo Therapeutics Codexis XOMA Vanda Pharmaceuticals Verastem Achieve Life Sciences Lexicon Pharmaceuticals (NASDAQ:LXRX) and AVEO Pharmaceuticals (NASDAQ:AVEO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Which has more volatility and risk, LXRX or AVEO? Lexicon Pharmaceuticals has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Is LXRX or AVEO more profitable? AVEO Pharmaceuticals has a net margin of -30.79% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. AVEO Pharmaceuticals' return on equity of -81.66% beat Lexicon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lexicon Pharmaceuticals-4,109.41% -107.38% -64.09% AVEO Pharmaceuticals -30.79%-81.66%-28.83% Do analysts recommend LXRX or AVEO? Lexicon Pharmaceuticals currently has a consensus target price of $6.00, indicating a potential upside of 645.99%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Lexicon Pharmaceuticals is more favorable than AVEO Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexicon Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75AVEO Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, LXRX or AVEO? AVEO Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexicon Pharmaceuticals$1.20M165.04-$177.12M-$0.75-1.07AVEO Pharmaceuticals$42.29M12.33-$53.34M-$0.84-17.86 Does the MarketBeat Community favor LXRX or AVEO? AVEO Pharmaceuticals received 7 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 70.68% of users gave AVEO Pharmaceuticals an outperform vote while only 64.86% of users gave Lexicon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexicon PharmaceuticalsOutperform Votes48064.86% Underperform Votes26035.14% AVEO PharmaceuticalsOutperform Votes48770.68% Underperform Votes20229.32% Do insiders and institutionals hold more shares of LXRX or AVEO? 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 50.0% of AVEO Pharmaceuticals shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of AVEO Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer LXRX or AVEO? In the previous week, Lexicon Pharmaceuticals had 16 more articles in the media than AVEO Pharmaceuticals. MarketBeat recorded 16 mentions for Lexicon Pharmaceuticals and 0 mentions for AVEO Pharmaceuticals. AVEO Pharmaceuticals' average media sentiment score of 0.25 beat Lexicon Pharmaceuticals' score of 0.25 indicating that AVEO Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Lexicon Pharmaceuticals Neutral AVEO Pharmaceuticals Neutral SummaryLexicon Pharmaceuticals beats AVEO Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXRX vs. The Competition Export to ExcelMetricLexicon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.05M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-1.075.5095.1214.22Price / Sales165.04375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book1.1210.276.976.37Net Income-$177.12M$153.22M$118.73M$225.56M7 Day Performance-24.12%-1.19%-1.22%-0.02%1 Month Performance-58.75%-6.71%-3.07%2.04%1 Year Performance-25.53%32.39%32.52%28.00% Lexicon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXRXLexicon Pharmaceuticals1.9831 of 5 stars$0.80-0.4%$6.00+646.0%-31.6%$198.05M$1.20M-1.07285Analyst RevisionAVEOAVEO PharmaceuticalsN/A$15.00flatN/A+0.0%$521.45M$42.29M-17.86114IRWDIronwood Pharmaceuticals4.2607 of 5 stars$3.36-4.5%$10.40+209.5%-63.0%$537.70M$442.73M-117.33220EBSEmergent BioSolutions4.3379 of 5 stars$9.47+6.6%$14.00+47.8%+322.9%$513.09M$1.05B-2.321,600Analyst DowngradeRIGLRigel Pharmaceuticals3.8438 of 5 stars$25.18+3.6%$31.30+24.3%+159.7%$443.42M$116.88M173.66147SGMOSangamo Therapeutics2.1854 of 5 stars$1.98+1.5%$7.00+253.5%+369.9%$413.13M$176.23M0.00480Analyst RevisionCDXSCodexis4.2117 of 5 stars$4.36+0.7%$8.33+91.1%+117.6%$354.82M$70.14M0.00250XOMAXOMA4.4424 of 5 stars$30.10+0.3%$78.50+160.8%+96.6%$354.58M$4.76M0.0010Positive NewsVNDAVanda Pharmaceuticals4.4351 of 5 stars$4.92+0.4%$15.50+215.0%+36.9%$286.89M$192.64M-17.50203VSTMVerastem2.8014 of 5 stars$4.07+7.4%$12.50+207.1%-41.2%$181.16M$2.60M-1.1950Analyst DowngradeAnalyst RevisionNews CoverageACHVAchieve Life Sciences1.4938 of 5 stars$4.34+0.9%$14.80+241.0%-21.9%$149.25MN/A0.0020 Related Companies and Tools Related Companies AVEO Alternatives IRWD Alternatives EBS Alternatives RIGL Alternatives SGMO Alternatives CDXS Alternatives XOMA Alternatives VNDA Alternatives VSTM Alternatives ACHV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LXRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXRX Stock Alerts